Silence Therapeutics combines explosive revenue growth and an engine-favored asymmetric setup with severe cash burn and volatile earnings, making it a high-risk, high-reward growth story.
Thesis pillars
- Extreme Cash Burn Rule Of 40 Fail→Stable
- Explosive Revenue Growth→Stable
- Overbought Momentum Asymmetric Upside→Stable
- +2 more pillars — see the Why tab for full reasoning
Silence Therapeutics Plc - Amer (SLN) Stock Analysis
Breakout setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $10.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.8/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality.
Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference) therapeutics via its mRNAi GOLD platform, with a pipeline led by divesiran (Phase 2, polycythemia vera) and zerlasiran (Phase 3-ready, cardiovascular disease driven by... Read more
Sell if holding. Engine safety override at $10.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.8/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Score 6.8/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Silence Therapeutics Plc - Amer
About Silence Therapeutics Plc - Amer
Silence Therapeutics, a London-based clinical-stage biopharmaceutical company trading via ADSs on Nasdaq, reported an $88.6 million net loss in 2025 against a $562.6 million accumulated deficit, with no products yet approved or generating revenue. Its lead rare-disease candidate, divesiran, is in a fully enrolled Phase 2 trial for polycythemia vera with topline results due in the third quarter of 2026, while zerlasiran, its Lp(a)-targeting cardiovascular candidate, is Phase 3 ready and awaiting a development partner.
As a pre-revenue company, Silence's income depends on collaboration and licensing deals rather than product sales: AstraZeneca funded and ran Phase 1 development of SLN312, an ANGPTL3-targeting candidate, but notified Silence on March 4, 2026 that it will not advance the program beyond Phase 1, returning full development, manufacturing, and commercialization rights to Silence. The company's mRNAi GOLD platform conjugates siRNA to GalNAc for targeted liver-cell delivery, a modality already validated in divesiran's Phase 1 SANRECO results, which eliminated therapeutic phlebotomies across 21 polycythemia vera patients dosed once every six weeks. Beyond the two lead programs, earlier-stage candidates include SLN548 (complement factor B, seeking a partner for clinical development), SLN365 (GPR146, cholesterol), and SLN098 (INHBE, obesity), all still in preclinical or early discovery. Clinical trial material is produced by third-party contract manufacturers rather than in-house facilities, a dependency the 10-K flags as a potential source of trial delay.
Show full overview
Silence's near-term commercial path runs through business development rather than its own trials: zerlasiran is explicitly described as awaiting a third-party partner for Phase 3 funding and future commercialization, and SLN548 likewise needs an outside partner just to begin clinical development, meaning two of the company's most derisked assets cannot advance without a deal Silence does not control the timing of. That dependency was reinforced in March 2026 when AstraZeneca, its only named large-pharma collaborator, opted out of SLN312 beyond Phase 1 — a decision that returns the asset to Silence but also removes an existing example of the partnership model the company is counting on to fund zerlasiran and SLN548.
See also: Healthcare · Biotechnology
From Silence Therapeutics Plc - Amer's most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-05-18Item 1.01LOWEntered into a new Open Market Sale Agreement (ATM) with Jefferies LLC for at-the-market ADS offerings, replacing the October 2021 agreement with Jefferies. Routine capital-raising facility; the company is not obligated to sell any ADSs under it.SEC filing →
- 2026-05-18Item 1.02MEDIUMTerminated the prior October 2021 Open Market Sale Agreement with Jefferies LLC, effective May 18, 2026, concurrent with entering a replacement ATM sales agreement with the same counterparty.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $10.81: Quality below floor (3.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 6.8/10 and A.R:R 8.7:1 is above the 1.5:1 BUY gate. Specifically: Elevated put/call ratio: 2.00; Below-average business quality. Chart setup: Golden cross, above all MAs, RSI 54, MACD bullish. Prior stop was $10.25. Score 6.8/10, moderate confidence.
Take-profit target: $25.38 (+130.3% upside). Prior stop was $10.25. Stop-loss: $10.25.
Quality below floor (3.5 < 4.0).
Silence Therapeutics Plc - Amer trades at a P/E of N/A (forward -28.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
What does Silence Therapeutics Plc - Amer do?Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference)...
Silence Therapeutics is a UK-based clinical-stage biopharmaceutical company developing siRNA (RNA interference) therapeutics via its mRNAi GOLD platform, with a pipeline led by divesiran (Phase 2, polycythemia vera) and zerlasiran (Phase 3-ready, cardiovascular disease driven by elevated Lp(a)). The company has never generated product revenue, relying on collaboration agreements such as its partnership with AstraZeneca on SLN312, and reported an $88.6 million net loss and $562.6 million accumulated deficit for 2025.